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Reduction in patient outcomes but implant- 
derived preservation of function following 
total knee arthroplasty: longitudinal  
follow- up of a randomized controlled trial
Aims
There are comparatively few randomized studies evaluating knee arthroplasty prostheses, 
and fewer still that report longer- term functional outcomes. The aim of this study was 
to evaluate mid- term outcomes of an existing implant trial cohort to document changing 
patient function over time following total knee arthroplasty using longitudinal analytical 
techniques and to determine whether implant design chosen at time of surgery influenced 
these outcomes.
Methods
A mid- term follow- up of the remaining 125 patients from a randomized cohort of total knee 
arthroplasty patients (initially comprising 212 recruited patients), comparing modern (Tri-
athlon) and traditional (Kinemax) prostheses was undertaken. Functional outcomes were 
assessed with the Oxford Knee Score (OKS), knee range of movement, pain numerical 
rating scales, lower limb power output, timed functional assessment battery, and satisfac-
tion survey. Data were linked to earlier assessment timepoints, and analyzed by repeated 
measures analysis of variance (AnOVA) mixed models, incorporating longitudinal change 
over all assessment timepoints.
Results
The mean follow- up of the 125 patients was 8.12 years (7.3 to 9.4). There was a reduction 
in all assessment parameters relative to earlier assessments. Longitudinal models high-
light changes over time in all parameters and demonstrate large effect sizes. Significant 
between- group differences were seen in measures of knee flexion (medium- effect size), 
lower limb power output (large- effect size), and report of worst daily pain experienced 
(large- effect size) favouring the Triathlon group. no longitudinal between- group differ-
ences were observed in mean OKS, average daily pain report, or timed performance test. 
Satisfaction with outcome in surviving patients at eight years was 90.5% (57/63) in the 
Triathlon group and 82.8% (48/58) in the Kinemax group, with no statistical difference 
between groups (p = 0.321).
Conclusion
At a mean 8.12 years, this mid- term follow- up of a randomized controlled trial cohort high-
lights a general reduction in measures of patient function with patient age and follow- up 
duration, and a comparative preservation of function based on implant received at time of 
surgery.
Cite this article: Bone Joint J 2020;102-B(4):434–441.
Introduction
Total knee arthroplasty (TKA) is highly effective 
at reducing the morbidity associated with osteo-
arthritis.1 Over 100,000 TKAs are carried out 
annually in the United Kingdom,2,3 and although 
results are generally satisfactory, up to 20% of 
recipients report a less than favourable outcome.4,5 
As such, implants for knee arthroplasty continually 
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Fig. 1
Flowchart showing trial CONSORT participation.
evolve in efforts to enhance patient outcomes. A plethora of 
developments in prosthesis kinematics have promised enhanced 
function. However, Carr et al6 noted that while the number 
of implants available had increased substantially in recent 
years, little or no evidence had been published of increased 
effectiveness.
Survivorship analysis is the standard evaluation of implant 
success. This identifies the revision rate of an implant but 
does not comment on patients’ quality of life or function. 
Additionally, revision surgery is comparatively rare within 
ten- year follow- up of primary TKA, with UK national data-
sets reporting implant survival of > 95%.2,3 Accordingly trials 
evaluating patient outcomes are necessary, in conjunction with 
survival analysis, to provide comprehensive information on the 
performance of implants. There are comparatively few random-
ized studies evaluating implant technologies, and fewer still 
that evaluate longer- term patient functional outcomes. Those 
that do tend to report minimal outcomes data at a single final 
follow- up timepoint and analyze this by simple two- way anal-
ysis with reference to the baseline data. This form of analysis 
does not account for any temporal change which can offer a 
more complete picture of recovery and outcome trajectories. 
We have reported a randomized controlled trial7 that contrasted 
a modern implant design (Triathlon, Stryker, Mahwah, New 
Jersey, USA), against a previous model, that was routinely used 
at our department (Kinemax, Stryker). In the first three years 
post- surgery, the Triathlon group outperformed the Kinemax 
group in terms of knee flexion achieved, lower limb power 
output achieved, reported levels of ‘worst daily pain’ felt, and 
overall satisfaction with surgery.7
The aim of this follow- up study was to evaluate the outcomes 
of this implant trial cohort to chart changing patient function 
over time following TKA using longitudinal analytical tech-
niques and to determine if any between group differences in 
patient outcome remained at longer term follow- up.
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Table I. Summary of trial loss to follow- up.
Reason for loss to follow- up Kinemax, n Triathlon, n
Surgery
Operation delayed/cancelled 5 1
Non- trial surgeon reallocation 2 N/A
Six weeks postoperatively
Death 1 N/A
Revised (infection) 2 1
Patient withdrew (local follow- up) 9 3
Impaired health prohibited assessment 2 2
One year postoperatively
Not contactable/refused follow- up N/A 1
Three years postoperatively
Death 4 8
Revised 1 N/A
Not contactable/refused follow- up 2 2
Impaired health prohibited assessment 1 N/A
eight years postoperatively
Death 10 8
Revised 1 3
Not contactable/refused follow- up 2 7
Impaired health prohibited assessment 3 6
N/A, not applicable.
Table II. Comparative group characteristics of the surviving cohort.
Kinemax Triathlon p- value
Implants, n 59 66 N/A
Mean follow- up, yrs (range) 8.08 (7.89 to 
8.78)
8.11 (7.31 to 
9.24)
N/A
Female, n (%) 34 (58%) 42 (63%) 0.58*
Mean age, yrs (SD) 74.8 (8.3) 75.4 (7.6) 0.69†
Mean baseline OKS (SD) 20.19 (7.6) 19.11 (7.3) 0.16†
Mean baseline ‘average’ pain 
(SD)
5.41 (1.6) 5.36 (1.6) 0.87†
Mean baseline ‘worst’ pain 
(SD)
8.04 (1.6) 8.52 (1.3) 0.09†
Mean baseline ROM, ° (SD) 105.38 (15.4) 105.71 (15.2) 0.93†
Mean baseline timed function, 
(SD)
32.72 (10.5) 32.50 (10.5) 0.82†
Mean baseline power output, 
% cont. limb (SD)
51.13 (37.9) 49.77 (32.9) 0.74†
*Chi- squared test.
†Independent samples t- test.
OKS, Oxford Knee Score; ROM, range of movement; SD, standard 
deviation.
Methods
This study follows a cohort of 212 patients (mean age 69, 131 
(62%) female) who were recruited to a prospective, double- 
blind, randomized control trial to assess the influence of TKA 
prosthetic design on patient functional outcome. The study 
was registered with the International Standard Randomized 
Controlled Trial Number Register (ISRCTN85418379).
Full methodological details are presented in the initial study 
report.7 Ethical approval was granted by the Lothian Research 
Ethics Committee 03 (ref: 06/S1103/50). Recruitment took 
place between February 2008 and August 2009. Patients were 
recruited through informed consent. Implant allocation was 
by internet- based computer randomization, both patient and 
researcher were blinded to implant allocation, and remained 
so up to reporting at three years. It was initially hoped to 
review this cohort at five years, but logistical delays resulted 
that sequential review was facilitated at a later time period. All 
‘new’ timepoint functional tests were carried out by the same 
researcher independent of the surgical teams blinded to implant 
allocation; however, we assume continued participant blinding 
has been lost. We did not formally unblind the trial, but it was 
ethically unreasonable (and logistically impractical) to attempt 
to maintain secrecy about implant allocation beyond the orig-
inal study period and we assumed patients had become aware 
of their allocation.
The intervention implants were the Kinemax and Triathlon 
prostheses. Surgery and postoperative care for all patients in 
the study was standardized as per our unit’s routine proto-
cols. Implants were inserted via the same surgical technique 
employing cemented, cruciate- retaining, fixed- bearing implants 
in all cases. The patella was not resurfaced in accordance with 
the units’ standard practice.
Outcome assessments. Efforts were made to contact all pa-
tients (including those previously reported lost to follow- up), 
and local health records checked for death and revision of 
implant. Patients were evaluated using the same equipment at 
the same clinical testing facility. Evaluation comprised the bat-
tery of assessment parameters previously reported. Initially as 
part of this study we also collected the Western Ontario and 
McMaster Universities Osteoarthritis Index8 (WOMAC) score, 
but use of this questionnaire was abandoned during the first 
year of follow- up due to poor patient compliance with comple-
tion and resultant unusable data. We instead focussed our efforts 
on collecting the primary outcome questionnaire and functional 
testing data, which were well tolerated by the participants.
The Oxford Knee Score (OKS), is a 12- item response 
questionnaire designed to assess the patient’s perceived pain 
and functional ability.9 Scores range from 0 (representing 
severe symptoms and dysfunction) to 48 (representing a well- 
functioning knee joint).Global knee- pain severity was assessed 
using an 11 point (0 to 10) numerical rating scale (NRS), where 
0 represents no pain and 10 the worst possible pain. Sepa-
rate assessments were made of ‘worst pain’ and ‘perceived 
average daily pain’ to provide more realistic and meaningful 
measurements of pain intensity.10 Active measures of flexion 
were determined using a standardized universal goniometry 
testing protocol as described by Jakobsen et al.11 Testing was 
conducted supine, with no encumbrance from clothing, using a 
long- arm goniometer with measurements recorded to 1° inter-
vals. The patient’s lower limb power was determined with a 
Leg Extensor Power Rig (Nottingham University, Nottingham, 
UK). Output is expressed as a proportion of the measured result 
obtained preoperatively from the contralateral limb to act as an 
internal control, and to guard against the confounding influ-
ence of progressive disease pathology in the contralateral limb. 
Those not able to complete the test were assigned a score of 
zero as advocated by Lamb and Frost.12 The ability to perform 
daily functional tasks was assessed with the aggregated loco-
motor function (ALF) score; a composite timed measure of 
observed tests of walking, stair ascent/decent, and chair trans-
fers.13 Time was recorded using a handheld stopwatch (Zeon, 
London, United Kingdom). Patient satisfaction with outcome at 
eight years was assessed with a five- point Likert scale; response 
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Fig. 2
Chart showing mean Oxford Knee Score (eight- year cohort) with 95% 
confidence intervals.
Fig. 3
Chart showing reported mean ‘average daily pain’ experienced (eight- 
year cohort) with 95% confidence intervals.
Fig. 4
Chart showing report of worst mean daily pain experienced (eight- year 
cohort) with 95% confidence intervals.
Fig. 5
Chart showing mean maximal knee flexion (eight- year cohort) with 95% 
confidence intervals.
Fig. 6
Chart showing mean lower limb power output (eight- year cohort) with 
95% confidence intervals.
Fig. 7
Chart showing timed mean functional performance score (eight- year 
cohort) with 95% confidence intervals.
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Table III. Satisfaction with outcome by group: eight- year cohort.*
Satisfaction response Kinemax, n Triathlon, n Total, n
Very satisfied 36 38 74
Satisfied 12 19 31
Uncertain 8 3 11
Dissatisfied 1 3 4
Very dissatisfied 1 0 1
Total 58 63 121
*Missing data/no response n = 4.
Table IV. Longitudinal assessment of outcome parameter incorporating 
change across all time point evaluations.
Outcome parameter Change over time* Between- group 
difference†
Oxford Knee Score F = 152.7, p < 0.001, 
ηp2 = 0.58
F = 1.7, p = 0.14, ηp2 
= 0.15
Mean ‘average daily pain’ F = 132.5, p < 0.001, 
ηp2 = 0.53
F = 0.7, p = 0.74, ηp2 
= 0.07
Worst daily pain F = 66.6, p < 0.001, 
ηp2 = 0.58
F = 2.8, p = 0.04, ηp2 
= 0.21
Knee flexion F = 27.6, p < 0.001, 
ηp2 = 0.20
F = 1.9, p = 0.05, ηp2 
= 0.12
Proportional lower limb 
power
F = 66.7, p < 0.001, 
ηp2 = 0.45
F = 2.9, p = 0.01, ηp2 
= 0.33
Timed performance test F = 34.1, p < 0.001, 
ηp2 = 0.24
F = 1.2, p = 0.29, ηp2 
= 0.11
*Longitudinal mixed model.
†Analysis of variance implant time interaction.
F = F- ratio, ηp2= partial Eta squared (measure of effect size).
options were very satisfied, satisfied, unsure, dissatisfied, and 
very dissatisfied.
The patients. From the originally recruited patients, a total 
of 125 patients (59 Kinemax and 66 Triathlon) were availa-
ble for analysis at a mean 8.12 years follow- up (7.31 to 9.24) 
(Figure 1). This represents a loss to follow- up of 40 patients in 
the five years since last data reporting. Reasons for this loss in-
clude death (n = 18), comorbidity preventing further evaluation 
(n = 9), failed to contact or declined further evaluation (n = 9), 
and revision of implant (n = 4). Overall loss to follow- up was 
now 41% (87 of 212 patients) and full trial loss to follow- up is 
detailed in the study CONSORT flowchart (Figure 1) with pa-
tient attrition by review timepoint summarized in Table I.
Statistical analysis. Analysis was undertaken of the surviving 
patients who we were able to review eight years after the prima-
ry surgery. Means are presented with standard deviations (SDs) 
or 95% confidence intervals (CIs) as a measure of dispersion. 
Baseline data comparisons were evaluated with chi- squared and 
independent samples t- tests as appropriate. Final timepoint data 
were contrasted using unpaired t- tests and chi- squared test for 
the satisfaction data. Primary analysis was evaluation of change 
in outcome assessment parameters over time (encompassing the 
earlier outcome timepoints), with subsequent between group 
implant- time interactions using repeated measures analysis of 
variance (ANOVA) generalized linear mixed models. Statistical 
significance was set at a p- value ≤ 0.05. ANOVA effect size is 
interpreted according to Cohen’s benchmarks.14 Data were col-
lated and analyzed using SPSS v. 21 (IBM, Chicago, Illinois, 
USA).
Results
The overall all- cause revision rate from the originally recruited 
212 patients is equivalent between groups at 3.8% (n = 4) in the 
Kinemax group and 3.7% (n = 4) in the Triathlon group. We 
previously reported three early septic revisions (two Kinemax 
and one Triathlon) and one aseptic revision for persistent pain 
by three years (Kinemax). The four ‘new’ revisions occurring 
between three and eight years were all aseptic failures; two were 
documented as being aseptic loosening of the tibial component 
(one per implant group), one as pain and instability secondary 
to femoral component rotational malalignment (Triathlon) and 
one as pain following a fall (Triathlon).
To ensure the remaining patients represent a balanced cohort, 
considering the loss to follow- up by eight- year review, compar-
ative analysis was performed on demographic indicators and 
baseline scores of evaluable patients (Table II). There are no 
differences between groups in presenting case- mix in the 
remaining cohort of 125 patients.
Functional outcomes at eight years. All outcome parameters, 
which had been broadly stable between six months and three 
years, now show signs of worsening in the five years since last 
follow- up (Figures 2 to 7). At eight years, mean OKS in the 
Kinemax group is 33.6 (95% CI 31.4 to 36.8), and 35.5 (95% 
CI 32.5 to 38.5) in the Triathlon group (p = 0.140, independent 
samples t- test). Mean ‘average daily pain’ experienced is 2.5 
(95% CI 1.8 to 3.1) in the Kinemax group and 1.8 (95% CI 
1.2 to 2.3) in the Triathlon group (p = 0.066, independent sam-
ples t- test). Mean worst daily pain experienced is 3.8 (95% CI 
2.9 to 4.7) in the Kinemax group and 3.4 (95% CI 2.6 to 4.3) 
in the Triathlon group (p = 0.470, independent samples t- test). 
Mean maximal active flexion is 97.7° (95% CI 95.1 to 100.3) in 
the Kinemax group and 102.5° (95% CI 100.1 to 104.9) in the 
Triathlon group (p = 0.003, independent samples t- test). Mean 
proportional lower limb power output is 73.2% (95% CI 61.7 to 
84.8) in the Kinemax group and 88.6% (95% CI 76.1 to 101.2) 
in the Triathlon group (p = 0.137, independent samples t- test). 
Mean aggregated timed functional performance test is 32.4 sec-
onds (95% CI 28.7 to 36.1) in the Kinemax group and 30.1 sec-
onds (95% CI 26.6 to 33.5) in the Triathlon group (p = 0.307, 
independent samples t- test).
Generally high levels of satisfaction with outcome were 
seen in the cohort with 82.8% (48/58) of the Kinemax group 
and 90.5% (57/63) of the Triathlon reporting a positive satis-
faction response (either satisfied or very satisfied). However, 
between- group difference in satisfaction response at eight- year 
assessment did not reach statistical significance (p = 0.321, chi- 
squared test), Table III.
Longitudinal analysis. Longitudinal models highlight changes 
over time in all longitudinal parameters and demonstrate large 
effect sizes. Significant between- group differences were seen in 
measures of knee flexion (with a medium effect size), lower 
limb power output (large effect size), and report of worst dai-
ly pain experienced (large effect size) favouring the Triathlon 
group. No longitudinal between- group differences were ob-
served in mean OKS, report of average daily pain report, or 
timed performance test (Table IV, Figures 2 to 7).
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Discussion
The main finding of this study was that patient outcomes, as 
assessed by a variety of parameters, generally deteriorated over 
time following knee arthroplasty, with a notable dip in perfor-
mance occurring between the early follow- ups and the eight- 
year review. Implant design also seems to influence facets of 
patient functional outcome in the medium term.
At a mean of 8.12 years (7.3 to 9.4) follow- up, the Triathlon 
group demonstrate statistically significantly superior results, 
across all trial timepoints, to the Kinemax group in measures 
of knee flexion, proportional lower limb power output and 
report of worst daily pain experienced; demonstrating medium 
to large effect sizes for these differences. There were no statis-
tically significant between- group differences seen in OKS, 
average daily pain experienced, or timed performance assess-
ment of activities of daily living. A single timepoint evaluation 
of satisfaction demonstrated no statistical difference between 
the groups.
Historically, implant survival has been the usual method of 
comparing different implant designs over time. The survivorship 
of modern implants (including those employed in this study) is 
high regardless of fixation, constraint, and bearing type. Indeed, 
the most recent data in the National Joint Registry for England, 
Wales, Northern Ireland and Isle of Man (NJR) highlights 
both implants to have > 96% survival at ten years.2 Another 
recognized problem with focussing on revision rate in isola-
tion is that it does not comment on the quality of patient func-
tion or health status prior to revision of the implant. Assuming 
prosthesis benchmarking standards are met, ‘survival’ of the 
implant is something of a poor differentiator of outcome. We 
have previously highlighted that patient attrition among arthro-
plasty cohorts are not particularly well reported when consid-
ering implant survival.7 In total, 183 patients were active on this 
study at one- year review; it is perhaps sobering that since then, 
58 patients have been lost to follow- up (32% of the one- year 
cohort) with only five of these being implant- related. A total 
of 31 are now dead and a further nine have impaired health 
to the extent they cannot be actively reviewed (e.g. residential 
nursing home care with pathologies such as vascular dementia). 
The active cohort is now 59% of those initially recruited (125 
of 212 participants).
It is of note that the outcome scores across the cohort have 
generally deteriorated between three- and eight- year reviews. 
We assume that the worsening outcome scores simply reflect 
an ageing study cohort eight years following surgery; the five- 
year advancement in time from last review sees the mean age of 
our cohort rise from early- to mid- 70s. Williams et al15 reported 
reduced OKS with advancing age using cross- sectional data. It 
is unsurprising that the physical measures (lower limb power 
output, time to perform functional activities, and maximal knee 
flexion) would reduce somewhat, perhaps regressing to a level 
appropriate to the demands of the patient’s lifestyle. Large scale 
cohort studies documenting physical changes with ageing note 
the reduction of lower limb muscle strength in older age,16 and 
the association between this decline in lower limb strength and 
increased impairment in mobility.17 We report lower limb power 
output relative to that of the contralateral limb collected at preop-
erative baseline assessment to act as a stable internal control 
across all future measurements. The trial arms demonstrated 
the same proportional power output preoperatively (approxi-
mately 50% of the control limb). However, the Triathlon group 
recovered differently and reports greater power compared to 
the preoperative control value by one year. We hypothesize that 
this may be mechanically supported via an increased moment 
arm in the quadriceps group as a result of the differing point 
of rotation in the knee joint (the Triathlon has a more posterior 
point of rotation than the Kinemax implant).7 It is important 
to highlight that the absolute lower limb power output values 
recorded in this study are below those of healthy age matched 
controls;18 the Triathlon group reports a comparative preserva-
tion of lower limb power compared with the Kinemax group 
and not an improvement compared to healthy populations.
Despite remaining generally low, pain scores have increased 
compared with previous values; whether this also reflects the 
ageing process or new pathology is unknown. The mean OKS 
has correspondingly reduced by around 2 points over this time, 
representing about half of the accepted minimum clinically 
detectable change in the score.19 It could be argued that, in 
terms of this key outcome parameter, there is a broadly stable 
outcome recorded between six months and eight years post-
operation supporting the longer- term benefits of knee arthro-
plasty. Alternatively, these data could be seen to point to a 
blunted measurement range and highlight the benefit of more 
detailed functional analyses of patients. The same argument 
applies to the timed performance test, which showed no differ-
ence between groups but the clustering of responses around the 
mean suggests a similar blunting of measurement range. This 
suggests that the between- group differences we report may 
relate to higher levels of function than are required for simple 
daily tasks such as ‘getting around the house’ and highlights the 
challenge faced by the orthopaedic community in choosing the 
most appropriate patient reported outcome measure and func-
tional test to gather relevant information across generic cohorts 
and highly performing groups.
In this study, the patients who received the more modern of 
the two implants demonstrate an overall comparative preserva-
tion of function at mean 8.12- year (7.3 to 9.4) review. Across 
the period since surgery, modest differences are evident between 
groups in absolute flexion (approximately 5°), report of worst 
pain experienced (approximately 10%), and ability to generate 
lower limb power in contrast to the control leg (approximately 
20%). The implant- derived differences persisting over multiple 
timepoint evaluation into the medium- term post arthroplasty is 
an interesting finding, suggesting these are absolute differences 
and the between- group change over time is proportional. The 
clinical relevance of the functional differences detected is hard 
to determine, particularly as they relate to the combined longi-
tudinal change as opposed to any specific timepoint difference. 
These changes cannot be readily interpreted with reference to a 
specific minimally important change in a metric, as such param-
eters have not been calculated over these longer periods. It can 
be speculated though that the modest reductions in reports of 
maximal pain, enhanced range of knee flexion, and greater 
ability to generate muscle power with the lower limb would be 
broadly beneficial and advantageous to both particularly frail 
and higher performing individuals.
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Strengths of this study were the original randomized controlled 
trial (RCT) design and both range and consistency of outcome 
measures employed, over a relatively long follow- up period.
The limitations of this study are that the cohort is from a 
single centre and that the ability to extrapolate the data to other 
settings is assumed but unknown. The longitudinal model-
ling we employ asks whether there is any change over time 
in the various metrics, and secondarily, whether there are any 
between- group differences across all the timepoints.
This trial was originally powered to detect a difference in 
OKS between preoperative and 12- month scores. Clearly the 
power of the study to detect differences between implant groups 
is reduced by both applying a longitudinal analysis (incorpo-
rating six evaluation times) and the continuing reduction in 
patient numbers at subsequent assessments. This increases 
the uncertainty around our point estimates and suggests that 
we are at increased risk of a type- II error in interpretation (i.e. 
failing to identify a positive result). We feel this analysis to be 
the most appropriate and conservative methodology to employ 
in evaluating the general effects over time; evaluating whether 
the overall temporal trajectory of outcomes differ between 
groups as opposed to focussing on any specific individual 
timepoint differences. A further limitation is that we cannot be 
sure that the study remains double- blind. Though the assessor 
was blind to implant allocation, the participants may have had 
this disclosed. We did not formally unblind the trial, however 
it is ethically unreasonable (and logistically impractical) to try 
to hide the implant allocation from patients beyond the orig-
inal study protocol. With five years having passed since last 
study visit, it is likely many patients would have seen various 
other orthopaedic clinical teams and may have had the implant 
name revealed. Although the patient reported scores could be 
influenced by confirmation bias, we think it unlikely that the 
physical evaluations (such as measures of knee flexion and 
power output) could have been meaningfully influenced by this 
knowledge.
In conclusion, at a mean 8.12- year follow- up, this random-
ized controlled trial cohort highlights a general reduction in 
measures of patient function with time following TKA and a 
comparative difference in function over time that is attributable 
to implant received at time of surgery.
Take home message
  - We demonstrate a comparative reduction in measures of 
patient physical function with increasing time following total 
knee arthroplasty.
  - In this RCT, we found that the implant used at time of surgery 
influenced outcome, with a modern design lineage implant moderating 
this functional decline.
Twitter
Follow D. F. Hamilton @df_hamilton
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